Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Supra R. Gajjala"'
Autor:
Dinesh Cyanam, Peter Wyngaard, Paul D. Williams, Mary Ellen Urick, Sean Eddy, Armand Bankhead, Daniel Rhodes, Supra R. Gajjala, Nickolay A. Khazanov, Mark Tomilo, Emma Bowden
Publikováno v:
Molecular Cancer Therapeutics. 12:C256-C256
Patients with chromosomal rearrangements resulting in fusion proteins are amongst the most responsive to targeted therapy. For example, targeting of the BCR-ABL fusion in chronic myelogenous leukemia (CML) with imatinib and the EML4-ALK fusion in non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea8d58bbbfbbd879ea0e86f8a528d227
https://doi.org/10.1158/1535-7163.targ-13-c256
https://doi.org/10.1158/1535-7163.targ-13-c256
Autor:
Santhoshi Bandla, Sean Eddy, Supra R. Gajjala, Daniel R. Rhodes, Peter Wyngaard, Seth Sadis, Paul D. Williams, Emma T. Bowden, Mark Tomilo, Nickolay A. Khazanov
Publikováno v:
Cancer Research. 73:2897-2897
The MAPK and PI3K pathways are frequently altered in human cancer and are targeted by dozens of agents in clinical trials. The successful application of these therapies, alone or in combination, may depend on the activation status of both pathways. N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c605edee540c04d4e8a86c8b39e9236b
https://doi.org/10.1158/1538-7445.am2013-2897
https://doi.org/10.1158/1538-7445.am2013-2897